Title

The case for cost sharing for biologic therapies

UMMS Affiliation

Meyers Primary Care Institute

Date

4-15-2006

Document Type

Article

Medical Subject Headings

Biological Agents; Cost Sharing; Cost-Benefit Analysis; Drug Costs; Humans; Managed Care Programs; Patient Participation; United States

Disciplines

Health Services Research | Pharmacy and Pharmaceutical Sciences | Primary Care

Abstract

Although there were few users of biologics in the past, today many more common conditions, such as rheumatoid arthritis, asthma, and hepatitis C, are being treated with biologics. Payers must be able to determine the true cost benefit of a therapy and provide this information to patients.

Comments

Citation: Am J Manag Care. 2006 Apr;12(6 Suppl):S159-61; discussion S167-72; quiz S173-6.

Related Resources

Link to Article in PubMed

PubMed ID

16613530